Director Grossman Jerrold B exercised 136,861 shares at a strike of $4.28 and sold $2,363,932 worth of shares (136,861 units at $17.27) (SEC Form 4)
$ADMA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 08/29/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 08/29/2024 | M | 118,861 | A | $3.66 | 586,166 | D | |||
| Common Stock | 08/29/2024 | M | 9,000 | A | $5.96 | 595,166 | D | |||
| Common Stock | 08/29/2024 | M | 9,000 | A | $10.8 | 604,166 | D | |||
| Common Stock | 08/29/2024 | S | 136,861 | D | $17.2725(1) | 467,305(2) | D | |||
| Common Stock | 22,857 | I | See Footnote(3) | |||||||
| Common Stock | 31,381 | I | See Footnote(4) | |||||||
| Common Stock | 38,294 | I | See Footnote(5) | |||||||
| Common Stock | 175 | I | See Footnote(6) | |||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Common Stock | $3.66 | 08/29/2024 | M | 118,861 | (7) | 06/06/2027 | Common Stock | 118,861 | $3.66 | 0 | D | ||||
| Common Stock | $5.96 | 08/29/2024 | M | 9,000(10) | (8) | 01/28/2026 | Common Stock | 9,000 | $5.96 | 0 | D | ||||
| Common Stock | $10.8 | 08/29/2024 | M | 9,000(10) | (9) | 01/30/2025 | Common Stock | 9,000 | $10.8 | 0 | D | ||||
| Explanation of Responses: |
| 1. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 2. Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person. |
| 3. These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood. |
| 4. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee. |
| 5. These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis. |
| 6. These shares are owned by the reporting person's wife. |
| 7. These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019. |
| 8. These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. |
| 9. These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017. |
| 10. The Reporting Person is exercising these options due, in part, to their near-term expiration date. |
| Remarks: |
| Exhibit 24 - Power of Attorney |
| /s/ Dr. Jerrold B. Grossman, by Adam S. Grossman as Attorney-in-fact | 08/30/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||